Introduction: As new therapeutics for metastatic renal cell carcinoma (mRCC) are quickly
introduced to market, comparative randomized trial evidence guiding treatment decisions is …

Purpose: Although narrow eligibility criteria improve the internal validity of clinical trials, they
may result in differences between study populations and real-world patients, threatening …

ABSTRACT The Metastatic Renal Cell Cancer Registry, a large, nationally representative,
prospective registry of patients with metastatic renal cell carcinoma (mRCC), aims to …

Background Vascular endothelial growth factor (VEGF), tyrosine kinase (TK) and
mechanistic target of rapamycin kinase (mTOR) inhibitors are common first-line (1 L) …

Background/Aim: Since the advent of targeted therapeutics, paradigms in metastatic renal
cell carcinoma (mRCC) treatment have changed. We investigated if efficacy and safety data …

Background Targeted therapies in metastatic renal cell carcinoma (mRCC) have been
approved based on registration clinical trials that have strict eligibility criteria. The clinical …

Objective The optimal sequencing of targeted therapies for metastatic renal cell carcinoma
(mRCC) is unknown. Observational studies with a variety of designs have reported differing …

Background New targeted therapeutics approved for metastatic renal cell carcinoma
(mRCC) offer multiple options in each line of therapy; however, there are few prospective …

Background: Vascular endothelial growth factor (VEGF) inhibitors, including targeted
therapy with tyrosine kinase inhibitors (TKIs) and the angiogenesis inhibitor bevacizumab …

Background Patient characteristics and survival outcomes in randomized trials may be
different from those in real-life clinical practice. The objective of this study was to describe …